261 related articles for article (PubMed ID: 23318310)
1. Economic savings versus health losses: the cost-effectiveness of generic antiretroviral therapy in the United States.
Walensky RP; Sax PE; Nakamura YM; Weinstein MC; Pei PP; Freedberg KA; Paltiel AD; Schackman BR
Ann Intern Med; 2013 Jan; 158(2):84-92. PubMed ID: 23318310
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of nucleoside reverse transcriptase inhibitor pairs in efavirenz-based regimens for treatment-naïve adults with HIV infection in the United States.
Brogan AJ; Talbird SE; Cohen C
Value Health; 2011; 14(5):657-64. PubMed ID: 21839403
[TBL] [Abstract][Full Text] [Related]
3. Comparative Pricing of Branded Tenofovir Alafenamide-Emtricitabine Relative to Generic Tenofovir Disoproxil Fumarate-Emtricitabine for HIV Preexposure Prophylaxis: A Cost-Effectiveness Analysis.
Walensky RP; Horn T; McCann NC; Freedberg KA; Paltiel AD
Ann Intern Med; 2020 May; 172(9):583-590. PubMed ID: 32150602
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness analysis of emtricitabine/tenofovir versus lamivudine/zidovudine, in combination with efavirenz, in antiretroviral-naive, HIV-1-infected patients.
Sánchez-de la Rosa R; Herrera L; Moreno S
Clin Ther; 2008 Feb; 30(2):372-81. PubMed ID: 18343275
[TBL] [Abstract][Full Text] [Related]
5. Cost-Effectiveness of Long-Acting Injectable HIV Preexposure Prophylaxis in the United States : A Cost-Effectiveness Analysis.
Neilan AM; Landovitz RJ; Le MH; Grinsztejn B; Freedberg KA; McCauley M; Wattananimitgul N; Cohen MS; Ciaranello AL; Clement ME; Reddy KP; Hyle EP; Paltiel AD; Walensky RP
Ann Intern Med; 2022 Apr; 175(4):479-489. PubMed ID: 35099992
[TBL] [Abstract][Full Text] [Related]
6. Cost effectiveness of atazanavir-ritonavir versus lopinavir-ritonavir in treatment-naïve human immunodeficiency virus-infected patients in the United States.
Broder MS; Chang EY; Bentley TG; Juday T; Uy J
J Med Econ; 2011; 14(2):167-78. PubMed ID: 21288058
[TBL] [Abstract][Full Text] [Related]
7. The cost-effectiveness of HLA-B*5701 genetic screening to guide initial antiretroviral therapy for HIV.
Schackman BR; Scott CA; Walensky RP; Losina E; Freedberg KA; Sax PE
AIDS; 2008 Oct; 22(15):2025-33. PubMed ID: 18784465
[TBL] [Abstract][Full Text] [Related]
8. Rilpivirine versus efavirenz with emtricitabine/tenofovir disoproxil fumarate in treatment-naïve HIV-1-infected patients with HIV-1 RNA ≤100,000 copies/mL: week 96 pooled ECHO/THRIVE subanalysis.
Behrens G; Rijnders B; Nelson M; Orkin C; Cohen C; Mills A; Elion RA; Vanveggel S; Stevens M; Rimsky L; Thorpe D; Bosse M; White K; Zhong L; DeMorin J; Chuck SK
AIDS Patient Care STDS; 2014 Apr; 28(4):168-75. PubMed ID: 24660840
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of NNRTI-based antiretroviral therapy initiated during acute HIV infection.
Gay CL; Mayo AJ; Mfalila CK; Chu H; Barry AC; Kuruc JD; McGee KS; Kerkau M; Sebastian J; Fiscus SA; Margolis DM; Hicks CB; Ferrari G; Eron JJ;
AIDS; 2011 Apr; 25(7):941-9. PubMed ID: 21487250
[TBL] [Abstract][Full Text] [Related]
10. Simplification of antiretroviral therapy to a single-tablet regimen consisting of efavirenz, emtricitabine, and tenofovir disoproxil fumarate versus unmodified antiretroviral therapy in virologically suppressed HIV-1-infected patients.
Dejesus E; Young B; Morales-Ramirez JO; Sloan L; Ward DJ; Flaherty JF; Ebrahimi R; Maa JF; Reilly K; Ecker J; McColl D; Seekins D; Farajallah A;
J Acquir Immune Defic Syndr; 2009 Jun; 51(2):163-74. PubMed ID: 19357529
[TBL] [Abstract][Full Text] [Related]
11. HIV preexposure prophylaxis in the United States: impact on lifetime infection risk, clinical outcomes, and cost-effectiveness.
Paltiel AD; Freedberg KA; Scott CA; Schackman BR; Losina E; Wang B; Seage GR; Sloan CE; Sax PE; Walensky RP
Clin Infect Dis; 2009 Mar; 48(6):806-15. PubMed ID: 19193111
[TBL] [Abstract][Full Text] [Related]
12. Prioritizing HIV comparative effectiveness trials based on value of information: generic versus brand-name ART in the US.
Pei PP; Weinstein MC; Li XC; Hughes MD; Paltiel AD; Hou T; Parker RA; Gaynes MR; Sax PE; Freedberg KA; Schackman BR; Walensky RP
HIV Clin Trials; 2015 Nov; 16(6):207-18. PubMed ID: 26651525
[TBL] [Abstract][Full Text] [Related]
13. [Budget impact of a set-dose combination of efavirenz-emtricitabine-tenofovir in the treatment of patients infected with HIV-1].
Oyagüez I; Casado MA; Cotarelo M; Ramírez-Arellano A; Mallolas J
Farm Hosp; 2009; 33(5):247-56. PubMed ID: 19775575
[TBL] [Abstract][Full Text] [Related]
14. Recent availability of two novel, fixed formulations of antiretroviral nucleoside analogues: a 12-month prospective, open-label survey of their practical use and therapeutic perspectives in antiretroviral-naive and -experienced patients.
Manfredi R; Calza L
AIDS Patient Care STDS; 2008 Apr; 22(4):279-90. PubMed ID: 18290748
[TBL] [Abstract][Full Text] [Related]
15. Cost-Effectiveness of Single- Versus Generic Multiple-Tablet Regimens for Treatment of HIV-1 Infection in the United States.
Sweet DE; Altice FL; Cohen CJ; Vandewalle B
PLoS One; 2016; 11(1):e0147821. PubMed ID: 26808503
[TBL] [Abstract][Full Text] [Related]
16. Tenofovir or zidovudine in three-drug combination therapy with one nucleoside reverse transcriptase inhibitor and one non-nucleoside reverse transcriptase inhibitor for initial treatment of HIV infection in antiretroviral-naïve individuals.
Spaulding A; Rutherford GW; Siegfried N
Cochrane Database Syst Rev; 2010 Oct; (10):CD008740. PubMed ID: 20927777
[TBL] [Abstract][Full Text] [Related]
17. Economic evaluation of weekends-off antiretroviral therapy for young people in 11 countries.
Tierrablanca LE; Ochalek J; Ford D; Babiker A; Gibb D; Butler K; Turkova A; Griffin S; Revill P;
Medicine (Baltimore); 2018 Feb; 97(5):e9698. PubMed ID: 29384848
[TBL] [Abstract][Full Text] [Related]
18. Patient-reported outcomes in virologically suppressed, HIV-1-Infected subjects after switching to a simplified, single-tablet regimen of efavirenz, emtricitabine, and tenofovir DF.
Hodder SL; Mounzer K; Dejesus E; Ebrahimi R; Grimm K; Esker S; Ecker J; Farajallah A; Flaherty JF;
AIDS Patient Care STDS; 2010 Feb; 24(2):87-96. PubMed ID: 20156091
[TBL] [Abstract][Full Text] [Related]
19. Durable efficacy and safety of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naive HIV-1-infected patients: final 5-year results from STARTMRK.
Rockstroh JK; DeJesus E; Lennox JL; Yazdanpanah Y; Saag MS; Wan H; Rodgers AJ; Walker ML; Miller M; DiNubile MJ; Nguyen BY; Teppler H; Leavitt R; Sklar P;
J Acquir Immune Defic Syndr; 2013 May; 63(1):77-85. PubMed ID: 23412015
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of DTG + ABC/3TC versus EFV/TDF/FTC for first-line treatment of HIV-1 in the United States.
Peng S; Tafazzoli A; Dorman E; Rosenblatt L; Villasis-Keever A; Sorensen S
J Med Econ; 2015; 18(10):763-76. PubMed ID: 25934146
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
